Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q4 2014 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ALLAKOS INC | 23 | Q2 2024 | 23.0% |
SUTRO BIOPHARMA INC | 23 | Q2 2024 | 10.1% |
Intercept Pharmaceuticals Inc | 20 | Q3 2023 | 24.0% |
ACLARIS THERAPEUTICS INC | 18 | Q2 2024 | 4.8% |
RHYTHM PHARMACEUTICALS INC | 18 | Q2 2024 | 2.4% |
VERONA PHARMA PLC | 17 | Q2 2024 | 3.9% |
NKARTA INC | 16 | Q2 2024 | 17.1% |
SYROS PHARMACEUTICALS INC | 16 | Q3 2022 | 11.6% |
ATRECA INC | 16 | Q1 2023 | 7.4% |
ALLOVIR INC | 16 | Q2 2024 | 0.7% |
View Samsara BioCapital, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-09-03 |
13F-HR | 2024-08-14 |
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR/A | 2023-08-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR/A | 2023-02-15 |
13F-HR | 2023-02-14 |
View Samsara BioCapital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.